Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis

被引：0

作者：

Sturm, A. ^{[1
]}

Sebastian, S. ^{[2
]}

Faye, A. S. ^{[3
]}

Armuzzi, A. ^{[4
]}

Buisson, A. ^{[5
]}

Halfvarson, J. ^{[6
]}

Zeissig, S. ^{[7
,8
]}

Kochar, B. ^{[9
]}

Maier, S. ^{[10
]}

Redondo, I ^{[10
]}

Moses, R. E. ^{[10
]}

Keohane, A. ^{[11
]}

Watanabe, K. ^{[12
]}

机构：

[1] DRK Kliniken Berlin Westend, Dept Gastroenterol, Berlin, Germany

[2] Hull Univ Teaching Hosp, IBD Unit, Kingston Upon Hull, England

[3] NYU Langone Hlth, Inflammatory Bowel Dis Ctr, New York, NY USA

[4] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy

[5] Univ Clermont Auvergne, CHU Clermont Ferrand, Serv Hepatogastroenterol, Inserm,3iHP, Clermont Ferrand, France

[6] Orebro Univ, Dept Gastroenterol, Orebro, Sweden

[7] Univ Med Greifswald, Dept Internal Med A, Greifswald, Germany

[8] Tech Univ TU Dresden, Med Fac, Dresden, Germany

[9] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA USA

[10] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA

[11] HaaPACS GmbH, Stat Europe, Schriesheim, Germany

[12] Univ Toyama, Dept Internal Med Inflammatory Bowel Dis, Toyama, Japan

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.1263

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1089

引用

页码：i2005 / i2006

页数：2

共 50 条

[41] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
Sandborn, William J.
Sands, Bruce E.
Kobayashi, Taku
Tuttle, Jay
Schmitz, Jochen
Durante, Michael
Higgs, Richard E.
Canavan, James
Siegel, Robert
Ferrante, Marc
GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
[42] Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis
J. Ignacio Fernández-Blanco
Guillermo Fernández-Díaz
Carlos Cara
María I. Vera
David Olivares
Carlos Taxonera
Digestive Diseases and Sciences, 2018, 63 : 731 - 737
[43] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIAL
Sandborn, William J.
Ferrante, Marc
Bhandari, Bal R.
Berliba, Elina
Hibi, Toshifumi
D'Haens, Geert R.
Tuttle, Jay
Krueger, Kathryn A.
Friedrich, Stuart
Durante, Michael
Arora, Vipin
Feagan, Brian G.
GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094
[44] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
Shin, S. Shin
Park, S. J.
Kim, Y.
Im, J. P.
Kim, H. J.
Lee, K. M.
Kim, J. W.
Jung, S. A.
Lee, J.
Kang, S. B.
Shin, S. J.
Kim, E. S.
Kim, Y. S.
Kim, T. O.
Kim, H. S.
Park, D. I.
Kim, H. K.
Kim, E. S.
Kim, Y. H.
Kim, D. H.
Teng, D.
Kim, J. H.
Kim, W. Y.
Choi, C. H.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
[45] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
Louis, E.
Panaccione, R.
Parkes, G.
Peyrin-Biroulet, L.
Ferrante, M.
Hisamatsu, T.
Siegmund, B.
Kalabic, J.
Levine, P.
Neimark, E.
Wallace, K.
Chen, S.
Cheng, L.
Duan, W. R.
Armuzzi, A.
Biederman, L.
Loftus, E.
Melmed, G.
Schreiber, S.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
[46] Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis
Sandborn, W. J.
Sands, B.
Kobayashi, T.
Tuttle, J.
Schmitz, J.
Durante, M.
Higgs, R.
Canavan, J. B.
Siegel, R.
Ferrante, M.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S59 - S60
[47] Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
Hart, A.
Blumenstein, I
Kobayashi, T.
Chaparro, M.
Fantini, M. C.
Fumery, M.
Keohane, A.
Dhesi, E.
Tian, T.
Redondo, I
Barnes, E. L.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1452 - i1454
[48] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
Rubin, David T.
Allegretti, Jessica R.
Panes, Julian
Shipitofsky, Nicole
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Feagan, Brian G.
Hisamatsu, Tadakazu
Lichtenstein, Gary R.
Bressler, Brian
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Dignass, Axel
GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
[49] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Louis, Edouard
Panaccione, Remo
Parkes, Gareth
Peyrin-Biroulet, Laurent
Ferrante, Marc
Takeuchi, Ken
Siegmund, Britta
Levine, Phillip
Kalabic, Jasmina
Neimark, Ezequiel
Wallace, Kori
Chen, Su
Duan, W. Rachel
Armuzzi, Alessandro
Biedermann, Luc
Loftus, Edward V.
Melmed, Gil
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625
[50] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Louis, Edouard
Panaccione, Remo
Parkes, Gareth
Pevrin-Biroulet, Laurent
Ferrante, Marc
Takeuchi, Ken
Siegmund, Britta
Levine, Phillip
Kalabic, Jasmina
Neimark, Ezequiel
Wallace, Kori
Chen, Su
Duan, W. Rachel
Armuzzi, Alessandro
Biedermann, Luc
Loftus, Edward
Melmed, Gil
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S3 - S3

← 1 2 3 4 5 →